Free HCV Peer-Reviewed PDF Bonanza!!!

Posted on May 25, 2015

From now until the end of the month only! Free HCV Peer-Reviewed PDF Bonanza!!!

To satisfy your educational needs, Elsevier Multimedia Publishing has made available approximately 40 new, peer-reviewed, full text articles for free! Please see below for a list of these articles, which can readily be accessed in our American Journal of Medicine Hepatitis C Resource Center (hepcresource.amjmed.com).

Note that ALL currently available, free, full text HCV peer-reviewed articles will be removed from the Resource Center by the end of this month!

As of June 1, up to 18 freely available peer-reviewed, HCV PDF articles, together with editorial choices and additional reading suggestions, will be rotated on the Resource Center on a monthly basis.

The AJM Hepatitis C Resource Center provides both primary care providers and specialists with continually updated treatment guidelines, and an up-to-date repository of informative, freely-available, full-text articles to encourage effective HCV screening and diagnosis, and to highlight the promise of novel treatment regimens.

Free HCV Peer-Reviewed PDF Bonanza!!! New peer-reviewed, full-text article in the section of our Resource Center focused toward Primary Care Providers

Internal PubMed links are provided for you to review the abstract only, please visit the American Journal of Medicine Hepatitis Resource Center (hepcresource.amjmed.com) to access the free full-text articles.

Hepatitis C: An Introduction for Primary Care Providers

Hepatitis C.

Webster DP, Klenerman P, Dusheiko GM.

Lancet. 2015 Mar 21;385(9973):1124-35. doi: 10.1016/S0140-6736(14)62401-6. Epub 2015 Feb 14. Review.

Screening and Diagnosis of Hepatitis C

Diagnostics for hepatitis C: an urgent need for action.

Denkinger CM, Kessel M.

Lancet Glob Health. 2015 Apr;3(4):e195. doi: 10.1016/S2214-109X(15)70092-6. No abstract available.

Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting andevaluation of guideline defined hepatitis risk scenarios.

Wolffram I, Petroff D, Bätz O, Jedrysiak K, Kramer J, Tenckhoff H, Berg T, Wiegand J; for the German “Check-Up 35+“ Study Group.

J Hepatol. 2015 Jan 21. pii: S0168-8278(15)00017-3. doi: 10.1016/j.jhep.2015.01.011. [Epub ahead of print]

Hepatitis C Treatment and Management in Primary Care Settings

Integrated Care Increases Treatment and Improves Outcomes of Patients With Chronic Hepatitis C Virus Infection and Psychiatric Illness or Substance Abuse.

Ho SB, Bräu N, Cheung R, Liu L, Sanchez C, Sklar M, Phelps TE, Marcus SG, Wasil MM, Tisi A, Huynh L, Robinson SK, Gifford A, Asch SM, Groessl EJ.

Clin Gastroenterol Hepatol. 2015 Feb 24. pii: S1542-3565(15)00161-5. doi: 10.1016/j.cgh.2015.02.022. [Epub ahead of print]

Free HCV Peer-Reviewed PDF Bonanza!!! New peer-reviewed, full-text articles in the section of the Resource Center focused toward Hepatologists, Gastroenterologists & Infectious Disease Specialists

Internal PubMed links provided for you to review the abstracts only, please visit the American Journal of Medicine Hepatitis C Resource Center (hepcresource.amjmed.com) to access the free full-text articles.

Hepatitis C: Introduction, Clinical Manifestations and Natural History

Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice.

Cento V, Tontodonati M, Di Maio VC, Bellocchi MC, Valenti F, Manunta A, Fortuna S, Armenia D, Carioti L, Antonucci FP, Bertoli A, Trave F, Cacciatore P, Angelico M, Navarra P, Neumann AU, Vecchiet J, Parruti G, Babudieri S, Perno CF, Ceccherini-Silberstein F.

Dig Liver Dis. 2015 Mar;47(3):233-41. doi: 10.1016/j.dld.2014.12.004. Epub 2014 Dec 27.

Retrospective cohort study of liver transplantation in the United Kingdom between 1994 and 2010: the impact of hepatitis C infection.

Edeghere O, Verlander NQ, Aboulhab J, Costella A, Harris HE, Balogun MA, Ramsay ME.

Public Health. 2015 Feb 25. pii: S0033-3506(15)00043-8. doi: 10.1016/j.puhe.2015.01.024. [Epub ahead of print]

A cost-effectiveness model to personalize antiviral therapy in naive patients with genotype 1 chronic hepatitis C.

Iannazzo S, Colombatto P, Ricco G, Oliveri F, Bonino F, Brunetto MR.

Dig Liver Dis. 2015 Mar;47(3):249-54. doi: 10.1016/j.dld.2014.12.008. Epub 2014 Dec 18.

HCV glycoprotein structures: what to expect from the unexpected.

Khan AG, Miller MT, Marcotrigiano J.

Curr Opin Virol. 2015 Mar 16;12:53-58. doi: 10.1016/j.coviro.2015.02.004. [Epub ahead of print] Review.

Clinical trial watch: Reports from the AASLD Liver Meeting®, Boston, November 2014.

Londoño MC, Abraldes JG, Altamirano J, Decaens T, Forns X.

J Hepatol. 2015 Jan 31. pii: S0168-8278(15)00059-8. doi: 10.1016/j.jhep.2015.01.028. [Epub ahead of print] Review.

Molecular epidemiology of newly acquired hepatitis C infections in England 2008-2011: Genotype, phylogeny and mutation analysis.

May S, Ngui SL, Collins S, Lattimore S, Ramsay M, Tedder RS, Ijaz S.

J Clin Virol. 2015 Mar;64:6-11. doi: 10.1016/j.jcv.2014.12.014. Epub 2014 Dec 27.

Drug-drug Interaction Profile of the All-Oral Anti-Hepatitis C Virus Regimen of Paritaprevir/Ritonavir, Ombitasvir and Dasabuvir.

Menon R, Badri P, Wang T, Polepally A, Zha J, Khatri A, Wang H, Hu B, Coakley E, Podsadecki T, Awni W, Dutta S.

J Hepatol. 2015 Jan 31. pii: S0168-8278(15)00057-4. doi: 10.1016/j.jhep.2015.01.026. [Epub ahead of print]

Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders.

Milazzo L, Cattaneo D, Calvi E, Gervasoni C, Mazzali C, Ronzi P, Peri AM, Ridolfo AL, D’Avolio A, Antinori S.

Int J Antimicrob Agents. 2015 Feb 21. pii: S0924-8579(15)00067-9. doi: 10.1016/j.ijantimicag.2014.12.035. [Epub ahead of print]

Resistance to hepatitis C virus: potential genetic and immunological determinants.

Mina MM, Luciani F, Cameron B, Bull RA, Beard MR, Booth D, Lloyd AR.

Lancet Infect Dis. 2015 Apr;15(4):451-460. doi: 10.1016/S1473-3099(14)70965-X. Epub 2015 Feb 19. Review.

IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferonand ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis.

Zheng H, Li M, Chi B, Wu XX, Wang J, Liu DW.

Clin Res Hepatol Gastroenterol. 2015 Mar 10. pii: S2210-7401(15)00039-X. doi: 10.1016/j.clinre.2015.01.009. [Epub ahead of print]

Screening and Diagnosis of Hepatitis C

Expression of Hepatitis C Virus Core and E2 antigenic recombinant proteins and their use for development of diagnostic assays.

Ali A, Nisar M, Idrees M, Rafique S, Iqbal M.

Int J Infect Dis. 2015 Mar 18. pii: S1201-9712(15)00071-5. doi: 10.1016/j.ijid.2015.03.010. [Epub ahead of print]

Diagnostics for hepatitis C: an urgent need for action.

Denkinger CM, Kessel M.

Lancet Glob Health. 2015 Apr;3(4):e195. doi: 10.1016/S2214-109X(15)70092-6. No abstract available.

Opioid substitution therapy is associated with increased detection of hepatitis C virus infection: a 15-year observational cohort study.

Larney S, Grebely J, Falster M, Swart A, Amin J, Degenhardt L, Burns L, Vajdic CM.

Drug Alcohol Depend. 2015 Mar 1;148:213-6. doi: 10.1016/j.drugalcdep.2014.12.027. Epub 2015 Jan 5.

HCV RNA measurement in samples with diverse genotypes using versions 1 and 2 of the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV test.

Pyne MT, Mallory M, Hillyard DR.

J Clin Virol. 2015 Apr;65:54-7. doi: 10.1016/j.jcv.2015.02.002. Epub 2015 Feb 7.

A novel method for the measurement of hepatitis C virus infectious titres using the IncuCyte ZOOM and its application to antiviral screening.

Stewart H, Bartlett C, Ross-Thriepland D, Shaw J, Griffin S, Harris M.

J Virol Methods. 2015 Mar 20;218:59-65. doi: 10.1016/j.jviromet.2015.03.009. [Epub ahead of print].

Hepatitis C Clinical Trials

Hepatitis C: only a step away from elimination?

[No authors listed]

Lancet. 2015 Mar 21;385(9973):1045. doi: 10.1016/S0140-6736(15)60584-0. No abstract available.

Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment.

Aspinall EJ, Hutchinson SJ, Janjua NZ, Grebely J, Yu A, Alavi M, Amin J, Goldberg DJ, Innes H, Law M, Walter SR, Krajden M, Dore GJ.

J Hepatol. 2015 Feb;62(2):269-77. doi: 10.1016/j.jhep.2014.09.001. Epub 2014 Sep 6.

Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis Ccirrhotic patients who failed a previous interferon based regimen – The ANRS CO20-CUPIC study.

Bailly F, Virlogeux V, Dufour C, Pradat P, Hézode C, Larrey D, Alric L, Samuel D, Bourlière M, Métivier S, Zarski JP, Fontaine H, Loustaud-Ratti V, Serfaty L, Bronowicki JP, Carrat F, Zoulim F; CUPIC Study Group.

Clin Res Hepatol Gastroenterol. 2015 Jan 27. pii: S2210-7401(15)00002-9. doi: 10.1016/j.clinre.2014.12.007. [Epub ahead of print]

Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).

Bourlière M, Bronowicki JP, de Ledinghen V, Hézode C, Zoulim F, Mathurin P, Tran A, Larrey DG, Ratziu V, Alric L, Hyland RH, Jiang D, Doehle B, Pang PS, Symonds WT, Subramanian GM, McHutchison JG, Marcellin P, Habersetzer F, Guyader D, Grangé JD, Loustaud-Ratti V, Serfaty L, Metivier S, Leroy V, Abergel A, Pol S.

Lancet Infect Dis. 2015 Apr;15(4):397-404. doi: 10.1016/S1473-3099(15)70050-2. Epub 2015 Mar 13.

Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome.

Cento V, Di Paolo D, Di Carlo D, Micheli V, Tontodonati M, De Leonardis F, Aragri M, Antonucci FP, Di Maio VC, Mancon A, Lenci I, Manunta A, Taliani G, Di Biagio A, Nicolini LA, Nosotti L, Sarrecchia C, Siciliano M, Landonio S, Pellicelli A, Gasbarrini A, Vecchiet J, Magni CF, Babudieri S, Mura MS, Andreoni M, Parruti G, Rizzardini G, Angelico M, Perno CF, Ceccherini-Silberstein F.

Dig Liver Dis. 2015 Feb;47(2):157-63. doi: 10.1016/j.dld.2014.11.010. Epub 2014 Nov 24.

Risk of microangiopathy in type 2 diabetes mellitus patients with or without chronic hepatitis C: Results of a retrospective long-term controlled cohort study.

Coppo C, Bonfanti D, Bo S, Giordanino C, Gallo M, Cococcia S, Ciccone G, Smedile A, Ciancio A, Bugianesi E, Fagoonee S, Pellicano R, Rizzetto M, Saracco GM.

Dig Liver Dis. 2015 Feb 7. pii: S1590-8658(15)00187-5. doi: 10.1016/j.dld.2015.01.157. [Epub ahead of print]

Hope for non-responders with hepatitis C virus and cirrhosis.

Dusheiko G, MacDonald D.

Lancet Infect Dis. 2015 Apr;15(4):363-5. doi: 10.1016/S1473-3099(15)70094-0. Epub 2015 Mar 13. No abstract available.

STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection.

Ferenci P, Asselah T, Foster GR, Zeuzem S, Sarrazin C, Moreno C, Ouzan D, Maevskaya M, Calinas F, Morano LE, Crespo J, Dufour JF, Bourlière M, Agarwal K, Forton D, Schuchmann M, Zehnter E, Nishiguchi S, Omata M, Kukolj G, Datsenko Y, Garcia M, Scherer J, Quinson AM, Stern JO; on behalf of the STARTVerso1 study group.

J Hepatol. 2015 Jan 2. pii: S0168-8278(14)00953-2. doi: 10.1016/j.jhep.2014.12.024. [Epub ahead of print]

Shorter treatments for hepatitis C: another step forward?

Foster GR.

Lancet. 2015 Mar 21;385(9973):1054-5. doi: 10.1016/S0140-6736(14)61600-7. Epub 2015 Jan 13. No abstract available.

A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection.

Hassanein T, Sims KD, Bennett M, Gitlin N, Lawitz E, Nguyen T, Webster L, Younossi Z, Schwartz H, Thuluvath PJ, Zhou H, Rege B, McPhee F, Zhou N, Wind-Rotolo M, Chung E, Griffies A, Grasela DM, Gardiner DF.

J Hepatol. 2015 Jan 2. pii: S0168-8278(14)00954-4. doi: 10.1016/j.jhep.2014.12.025. [Epub ahead of print].

Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.

Jensen D, Sherman KE, Hézode C, Pol S, Zeuzem S, Ledinghen V, Tran A, Elkhashab M, Younes ZH, Kugelmas M, Mauss S, Everson G, Luketic V, Vierling J, Serfaty L, Brunetto M, Heo J, Bernstein D, McPhee F, Hennicken D, Mendez P, Hughes E, Noviello S; on behalf of the HALLMARK-QUAD Study Team.

J Hepatol. 2015 Feb 19. pii: S0168-8278(15)00125-7. doi: 10.1016/j.jhep.2015.02.018. [Epub ahead of print]

Patients with chronic hepatitis C without advanced fibrosis and hepatocellular carcinoma: A retrospective clinical-pathological study.

K-Kutala B, Bedossa P, Guedj J, Asselah T, Martinot-Peignoux M, Duval X, Marcellin P.

Dig Liver Dis. 2015 Apr;47(4):296-302. doi: 10.1016/j.dld.2014.12.010. Epub 2014 Dec 25.

Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.

Kohli A, Osinusi A, Sims Z, Nelson A, Meissner EG, Barrett LL, Bon D, Marti MM, Silk R, Kotb C, Gross C, Jolley TA, Sidharthan S, Petersen T, Townsend K, Egerson D, Kapoor R, Spurlin E, Sneller M, Proschan M, Herrmann E, Kwan R, Teferi G, Talwani R, Diaz G, Kleiner DE, Wood BJ, Chavez J, Abbott S, Symonds WT, Subramanian GM, Pang PS, McHutchison J, Polis MA, Fauci AS, Masur H, Kottilil S.

Lancet. 2015 Mar 21;385(9973):1107-13. doi: 10.1016/S0140-6736(14)61228-9. Epub 2015 Jan 13.

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.

Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, Alric L, Bronowicki JP, Lester L, Sievert W, Ghalib R, Balart L, Sund F, Lagging M, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B.

Lancet. 2015 Mar 21;385(9973):1075-86. doi: 10.1016/S0140-6736(14)61795-5. Epub 2014 Nov 11. Erratum in: Lancet. 2015 Mar 21;385(9973):1074.

Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection.

Lawitz E, Sullivan G, Rodriguez-Torres M, Bennett M, Poordad F, Kapoor M, Badri P, Campbell A, Rodrigues L Jr, Hu Y, Pilot-Matias T, Vilchez RA.

J Infect. 2015 Feb;70(2):197-205. doi: 10.1016/j.jinf.2014.09.008. Epub 2014 Sep 22.

Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.

Molina JM, Orkin C, Iser DM, Zamora FX, Nelson M, Stephan C, Massetto B, Gaggar A, Ni L, Svarovskaia E, Brainard D, Subramanian GM, McHutchison JG, Puoti M, Rockstroh JK; PHOTON-2 study team.

Lancet. 2015 Mar 21;385(9973):1098-106. doi: 10.1016/S0140-6736(14)62483-1. Epub 2015 Feb 4.

Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4.

Moreno C, Hezode C, Marcellin P, Bourgeois S, Francque S, Samuel D, Zoulim F, Grange JD, Shukla U, Lenz O, Ouwerkerk-Mahadevan S, Fevery B, Peeters M, Beumont M, Jessner W.

J Hepatol. 2015 Jan 14. pii: S0168-8278(15)00002-1. doi: 10.1016/j.jhep.2014.12.031. [Epub ahead of print]

Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.

Reddy KR, Zeuzem S, Zoulim F, Weiland O, Horban A, Stanciu C, Villamil FG, Andreone P, George J, Dammers E, Fu M, Kurland D, Lenz O, Ouwerkerk-Mahadevan S, Verbinnen T, Scott J, Jessner W.

Lancet Infect Dis. 2015 Jan;15(1):27-35. doi: 10.1016/S1473-3099(14)71002-3. Epub 2014 Dec 5.

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.

Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, Kugelmas M, Murillo A, Weis N, Nahass R, Shibolet O, Serfaty L, Bourliere M, DeJesus E, Zuckerman E, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B.

Lancet. 2015 Mar 21;385(9973):1087-97. doi: 10.1016/S0140-6736(14)61793-1. Epub 2014 Nov 11.

Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon α plus ribavirin in chronic hepatitis C.

Vukotic R, Gamal N, Andreone P.

Dig Liver Dis. 2015 Feb;47(2):151-6. doi: 10.1016/j.dld.2014.11.002. Epub 2014 Nov 13.

Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.

Younossi ZM, Stepanova M, Afdhal N, Kowdley KV, Zeuzem S, Henry L, Hunt SL, Marcellin P.

J Hepatol. 2015 Mar 17. pii: S0168-8278(15)00192-0. doi: 10.1016/j.jhep.2015.03.014. [Epub ahead of print]

Free HCV Peer-Reviewed PDF Bonanza!!! Gone by June 1!


No Replies to "Free HCV Peer-Reviewed PDF Bonanza!!!"


    Join the discussion

    Some html is OK